Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 6/2017

01-12-2017 | Research Article

Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice

Authors: Ivan Vuletic, Kedi Zhou, Hui Li, Huichen Bai, Xiangxi Meng, Sihao Zhu, Yichen Ding, Jun Li, Hongfang Sun, Qiushi Ren

Published in: Molecular Imaging and Biology | Issue 6/2017

Login to get access

Abstract

Purpose

Preclinical imaging offers a useful tool for monitoring cancer biological behavior and therapy in vivo without the necessity of animal surgery. The following paper describes our examination of tumor progress and anti-angiogenic therapy with Bevacizumab on colon cancer subtypes (SW480 and SW620) by using different non-invasive real-time in vivo imaging techniques.

Procedures

Color Doppler ultrasound imaging (CDUI) was used to observe the formation of new blood vessels; a homemade fluorescence reflectance imaging (FRI) apparatus was mainly used to test the difference in VEGFR2 expression between the tumor subtypes. Briefly, 15 Balb/c nude mice bearing subcutaneous SW480 and SW620 xenografts were randomly divided into Control and Drug groups. Bevacizumab treatment lasted for 3 weeks. All images were captured pre- and post-treatment. At the end of experiment, all mice were euthanized, and tumor tissue was collected and analyzed by immunohistochemical staining.

Results

Expression of VEGFR2 was found to be slightly (10 %) but significantly higher for the SW620 cells than for SW480 cells. In addition, SW620 has shown to be more vascularized than SW480 subtype. After 3-week Bevacizumab therapy, no blood vessels were found within 83 % of SW620, while it was 67 % in SW480; the increase of SW620 tumor volume post-treatment was only 3.17-fold compared with the tumor volume pre-treatment, and 4.51-fold higher in SW480.

Conclusion

Our data suggest that SW480 and SW620 cell lines respond differently to Bevacizumab therapy in vivo. Because of higher vascularization, and subsequently higher reduction by drug of new blood vessels and tumor growth rate, xenografts derived from the metastatic SW620 cell line have a better chance of being successfully treated with Bevacizumab compared with those derived from the primary tumor SW480 cell line.
Appendix
Available only for authorised users
Literature
1.
Leibovitz A, Stinson JC, McCombs WB et al (1976) Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36:4562–4569PubMed
2.
Hewitt R, McMarlin A, Kleiner D et al (2000) Validation of a model of colon cancer progression. J Pathol 192:446–454CrossRefPubMed
3.
Wang H, Jinming Z, Jiahe T et al (2009) Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med 50:1857–1864CrossRefPubMed
4.
Sukhdeo K, Paranmban RI, Vidal JG et al (2013) Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. PLoS One 8:e53015CrossRefPubMedPubMedCentral
5.
6.
Wang H, Liu B, Tian J et al (2010) Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice. World J Gastroenterol 16(43):5416–5423CrossRefPubMedPubMedCentral
7.
Heenan SD (2004) Magnetic resonance imaging in prostate cancer. Nat Publ Group 7:282–288
8.
Cherry S (2006) Multimodality in vivo imaging systems: twice the power or double the trouble? Annu Rev Biomed Eng 8:35–62CrossRefPubMed
9.
Dort M, Rehemtulla A, Ross B (2008) PET and SPECT imaging of tumor biology: new approaches towards oncology drug discovery and development. Curr Comput Aided Drug Des 4(1):46–45CrossRefPubMedPubMedCentral
10.
Ji S, Zheng Y, Shao G (2013) Integrin αvβ3–targeted radiotracer 99mTc-3P-RGD2Useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3RGD2 therapy. Theranostics 3(11):816–830CrossRefPubMedPubMedCentral
11.
Vuletic I, Liu J, Wu H et al (2015) Establishment of an mKate2-expressing cell line for non-invasive real-time breast cancer in vivo imaging. Mol Imaging Biol 17:811–818CrossRefPubMed
12.
Huang D, Lan H, Liu et al (2015) Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution. Int J Clin Exp Med 8(6):8369–8376PubMedPubMedCentral
13.
Hasan M, Ho S, Owen D et al (2011) Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int J Cancer 129:2115–2123CrossRefPubMed
14.
Wang Y, Fei D, Vanderlaan M et al (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335–345CrossRefPubMed
15.
Kim T, Landen C, Lin Y et al (2009) Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther 8(23):2263–2272CrossRefPubMedPubMedCentral
16.
Thaker A, Razjouyan F, Woods D et al (2012) Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma. Int J Hyperth 28(8):766–775CrossRef
17.
Zhu H, Li Z, Mao S et al (2011) Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice. Cancer Gene Ther 18:884–896CrossRefPubMedPubMedCentral
18.
Roskoski RJ (2008) VEGF receptor protein–tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375:287–291CrossRefPubMed
19.
20.
Yancopoulos G, Davis S, Gale N et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242–248CrossRefPubMed
21.
22.
He K, Cui B, Li G et al (2012) The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). OncoTargets and Therapy 5:59–65PubMedPubMedCentral
Metadata
Title
Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice
Authors
Ivan Vuletic
Kedi Zhou
Hui Li
Huichen Bai
Xiangxi Meng
Sihao Zhu
Yichen Ding
Jun Li
Hongfang Sun
Qiushi Ren
Publication date
01-12-2017
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 6/2017
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-017-1048-z

Other articles of this Issue 6/2017

Molecular Imaging and Biology 6/2017 Go to the issue

Research Article

[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients

Erratum

Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer

Research Article

Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements

Research Article

Influence of Co-57 and CT Transmission Measurements on the Quantification Accuracy and Partial Volume Effect of a Small Animal PET Scanner

Research Article

In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2′-deoxy-2′-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models

Research Article

Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer